MMR

Pharma Stock Bounces on Spin-Off Plans

GSK has chart support in place

Deputy Editor
Jun 23, 2021 at 10:35 AM
facebook X logo linkedin


The shares of London-based GlaxoSmithKline PLC (NYSE:GSK) are up 3.5% to trade at $40.45 at last check, after the global healthcare company announced plans to spin off its consumer health business. Also of note, the new core and drug vaccine division has set targets of 5% sales growth and 10% profit growth by 2026.

A week ago today, the pharma stock traded as high as $41.44, its highest levels since a 12-month high of $42.40 on Aug. 12. Despite shedding 1.6% since then, GSK has chart support in place at its 40-day moving average, a trendline that hasn't been breached since mid March. Year-to-date, the shares are up 8%. 

In the options pits, sentiment has been more bearish than usual. At the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), GSK's put/call volume ratio stands higher than 88% of readings from the past year, showing long puts being picked up at a faster-than-usual rate.

These options are well-priced at the moment, too, from a volatility perspective. The stock's Schaeffer's Volatility Index (SVI) of 19% stands higher than 15% of all other readings in its annual range, implying that options players are pricing in relatively low volatility expectations at the moment.  It's also worth pointing out that GSK ranks low on the Schaeffer's Volatility Scorecard (SVS), with a score of just 18 out of 100. In other words, the security has consistently realized lower volatility than its options have priced in, making the stock a potential premium-selling candidate.

 

Follow us on X, Follow us on Twitter

 

Nvidia and its powerful chips are the face of artificial intelligence.

But while everyone’s patting Nvidia on the back for record earnings…

It’s quietly moved on to the next phase of AI it plans to conquer…

Nvidia recently unveiled essential blueprints for this crucial $1 trillion pivot.

Click here now and find out about the three companies Nvidia absolutely needs to succeed in this vital new AI frontier.
 (ad)